Ligand efficiency indices for effective drug discovery
- PMID: 23484756
- DOI: 10.1517/17460441.2.4.469
Ligand efficiency indices for effective drug discovery
Abstract
Successful drug discovery requires the optimization of a large number of variables ranging from strictly physicochemical parameters such as molecular weight to more complex parameters related to toxicity and bioavailability. Presently, structure-based methodologies influence many aspects of the drug discovery process from lead discovery to the final preclinical characterization. However, critical biological issues along the path to the market have diminished the impact and power of this methodology. The physicochemical properties of the novel chemical entities designed and guided by structural methods have become the subject of intense scrutiny from lead discovery to drug candidate. The idea of ligand efficiency (binding energy/non-hydrogen atoms) has recently emerged as a useful guide to optimize fragment and lead selection in the discovery process. More generalized concepts of ligand efficiency, related to efficiency per dalton and per unit of polar surface area, have also been introduced and will be discussed in the broader context. Preliminary results and trends obtained using ligand efficiencies as guides are reviewed and their future application to guide drug discovery will be discussed, as well as their integration into the structure-based drug design methods to make them more effective and numerically robust.
Similar articles
-
Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.Chem Res Toxicol. 2011 Sep 19;24(9):1420-56. doi: 10.1021/tx200211v. Epub 2011 Jul 26. Chem Res Toxicol. 2011. PMID: 21790149 Review.
-
Ligand binding efficiency: trends, physical basis, and implications.J Med Chem. 2008 Apr 24;51(8):2432-8. doi: 10.1021/jm701255b. Epub 2008 Apr 2. J Med Chem. 2008. PMID: 18380424
-
Compound optimization in early- and late-phase drug discovery: acceptable pharmacokinetic properties utilizing combined physicochemical, in vitro and in vivo screens.Curr Opin Drug Discov Devel. 2000 Jan;3(1):30-41. Curr Opin Drug Discov Devel. 2000. PMID: 19649835
-
Alternative variables in drug discovery: promises and challenges.Future Med Chem. 2014 Apr;6(5):577-93. doi: 10.4155/fmc.14.16. Future Med Chem. 2014. PMID: 24649959
-
Novel trends in high-throughput screening.Curr Opin Pharmacol. 2009 Oct;9(5):580-8. doi: 10.1016/j.coph.2009.08.004. Epub 2009 Sep 21. Curr Opin Pharmacol. 2009. PMID: 19775937 Review.
Cited by
-
Three-dimensional structures in the design of therapeutics targeting parasitic protozoa: reflections on the past, present and future.Acta Crystallogr F Struct Biol Commun. 2015 May;71(Pt 5):485-99. doi: 10.1107/S2053230X15004987. Epub 2015 Apr 16. Acta Crystallogr F Struct Biol Commun. 2015. PMID: 25945701 Free PMC article. Review.
-
Small molecule inhibition of the Na(+)/H(+) exchange regulatory factor 1 and parathyroid hormone 1 receptor interaction.Biochemistry. 2014 Sep 23;53(37):5916-22. doi: 10.1021/bi500368k. Epub 2014 Sep 15. Biochemistry. 2014. PMID: 25171053 Free PMC article.
-
Merging allosteric and active site binding motifs: de novo generation of target selectivity and potency via natural-product-derived fragments.ChemMedChem. 2015 Mar;10(3):451-4. doi: 10.1002/cmdc.201402478. Epub 2014 Dec 8. ChemMedChem. 2015. PMID: 25487909 Free PMC article.
-
The FMO2 analysis of the ligand-receptor binding energy: the Biscarbene-Gold(I)/DNA G-Quadruplex case study.J Comput Aided Mol Des. 2022 Dec;36(12):851-866. doi: 10.1007/s10822-022-00484-z. Epub 2022 Nov 1. J Comput Aided Mol Des. 2022. PMID: 36318393
-
Developing inhibitors of glycan processing enzymes as tools for enabling glycobiology.Nat Chem Biol. 2012 Jul 18;8(8):683-94. doi: 10.1038/nchembio.1029. Nat Chem Biol. 2012. PMID: 22810773 Review.
LinkOut - more resources
Full Text Sources
Other Literature Sources